TY - JOUR
T1 - Microfibrous Solid Dispersions of Poorly Water-Soluble Drugs Produced via Centrifugal Spinning
T2 - Unexpected Dissolution Behavior on Recrystallization
AU - Marano, Stefania
AU - Barker, Susan A.
AU - Raimi-Abraham, Bahijja T.
AU - Missaghi, Shahrzad
AU - Rajabi-Siahboomi, Ali
AU - Aliev, Abil E.
AU - Craig, Duncan Q.M.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Temperature-controlled, solvent-free centrifugal spinning may be used as a means of rapid production of amorphous solid dispersions in the form of drug-loaded sucrose microfibers. However, due to the high content of amorphous sucrose in the formulations, such microfibers may be highly hygroscopic and unstable on storage. In this study, we explore both the effects of water uptake of the microfibers and the consequences of deliberate recrystallization for the associated dissolution profiles. The stability of sucrose microfibers loaded with three selected BCS class II model drugs (itraconazole (ITZ), olanzapine (OLZ), and piroxicam (PRX)) was investigated under four different relative humidity conditions (11, 33, 53, and 75% RH) at 25 °C for 8 months, particularly focusing on the effect of the highest level of moisture (75% RH) on the morphology, size, drug distribution, physical state, and dissolution performance of microfibers. While all samples were stable at 11% RH, at 33% RH the ITZ-sucrose system showed greater resistance against devitrification compared to the OLZ- and PRX-sucrose systems. For all three samples, the freshly prepared microfibers showed enhanced dissolution and supersaturation compared to the drug alone and physical mixes; surprisingly, the dissolution advantage was largely maintained or even enhanced (in the case of ITZ) following the moisture-induced recrystallization under 75% RH. Therefore, this study suggests that the moisture-induced recrystallization process may result in considerable dissolution enhancement compared to the drug alone, while overcoming the physical stability risks associated with the amorphous state.
AB - Temperature-controlled, solvent-free centrifugal spinning may be used as a means of rapid production of amorphous solid dispersions in the form of drug-loaded sucrose microfibers. However, due to the high content of amorphous sucrose in the formulations, such microfibers may be highly hygroscopic and unstable on storage. In this study, we explore both the effects of water uptake of the microfibers and the consequences of deliberate recrystallization for the associated dissolution profiles. The stability of sucrose microfibers loaded with three selected BCS class II model drugs (itraconazole (ITZ), olanzapine (OLZ), and piroxicam (PRX)) was investigated under four different relative humidity conditions (11, 33, 53, and 75% RH) at 25 °C for 8 months, particularly focusing on the effect of the highest level of moisture (75% RH) on the morphology, size, drug distribution, physical state, and dissolution performance of microfibers. While all samples were stable at 11% RH, at 33% RH the ITZ-sucrose system showed greater resistance against devitrification compared to the OLZ- and PRX-sucrose systems. For all three samples, the freshly prepared microfibers showed enhanced dissolution and supersaturation compared to the drug alone and physical mixes; surprisingly, the dissolution advantage was largely maintained or even enhanced (in the case of ITZ) following the moisture-induced recrystallization under 75% RH. Therefore, this study suggests that the moisture-induced recrystallization process may result in considerable dissolution enhancement compared to the drug alone, while overcoming the physical stability risks associated with the amorphous state.
KW - amorphous
KW - centrifugal spinning
KW - crystallization
KW - microfiber
KW - poorly water-soluble drug
KW - solid dispersion
KW - stability
KW - sucrose
KW - supersaturation
UR - http://www.scopus.com/inward/record.url?scp=85018374298&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.6b01126
DO - 10.1021/acs.molpharmaceut.6b01126
M3 - Article
C2 - 28296409
AN - SCOPUS:85018374298
SN - 1543-8384
VL - 14
SP - 1666
EP - 1680
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 5
ER -